Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer

Part of paid clinical trials in Stanford, California.

Sponsor
Northwestern University
Study ID
NCT00004182
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent breast cancer.

Key Dates

Start date
Oct 31, 1999
Status verified
May 2012
Primary completion
Apr 30, 2000
Completion
Apr 30, 2000

Study Design

Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Stanford University Medical CenterStanfordCalifornia94305-5408-
Robert H. Lurie Comprehensive Cancer Center, Northwestern UniversityChicagoIllinois60611-

Find similar trials in Stanford, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Stanford University Medical Center· Stanford, CARobert H. Lurie Comprehensive Cancer Center, Northwestern University· Chicago, IL

Related Studies